featured
Dr. Warren Heymann on Brentuximab Vedotin Update and the #MeToo Saga of the Reed-Sternberg Cell
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Terezakis S. Dorothy Reed Mendenhall: Expressions of a pioneer in Hodgkin disease. Int J Radiat Oncol Biol Phys. 2015;92(1):8-10.
- Zwitter M, Cohen JR, Barrett A, Robinton ED. Dorothy Reed and Hodgkin’s disease: A reflection after a century. Int J Radiation Oncology Biol Phys. 2002;53(2):366-375.
- Sadeghpour M, Bernstein I, Ko C, Jacobe H. Role of sex in academic dermatology: Results from a national survey. Arch Dermatol. 2012;148(7):809-814.
- ADCETRIS® (brentuximab vedotin). Package insert. Seattle Genetics, Inc.
- Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: A review and analysis of existing data. Int J Dermatol. 2017;56(12):1400-1405.
- Stranzenbach R, Dippel E, Schlaak M, Stadler R. Bretuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol. 2017;177(6):1503-1509.
- Lewis DJ, Talpur R, Huen AO, et al. Brentuximab vedotin for patients with refractory lymphomatoid papulosis. JAMA Dermatol. 2017;153(12):1302-1306.
- Prince HM, Kim YH, Horwitz SM, et al; ALCANZA Study Group. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3 multicentre trial. Lancet. 2017;390(10094):555-566.
- Zhang C, Chairatchaneeboon M, Haun P, et al. Treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin. JAMA Dermatol. 2018;154(1):109-110.